Additional (including spot views and SPECT) images s hould be sub mitted if acquired. Assessments should be performed at baseline and at the time points described per PCWG3 criteria until disease progression per PCWG3 criteria (see Appendix 11), or discontinuation of study treatment, whichever occurs later. Tumor assessments at other time points may be performed if clinically indicated and should be confirmed at least 4 weeks after init ial res ponse. Changes in tumor measurements and tumor res ponses will be assessed by the investigator per study design using PCWG3 criteria. Investigators will also re port the number and size of new lesions that appear while on study. For participants who are treated beyond PC WG3-defined progression, tumor assessments will continue to be performed until discontinuation of study treatment (typically upon evidence of further progression). Any addition al imaging that may demonstrate tumor response or progression (including scans performed at unscheduled time points and/or at an outside institution should be collected for PCWG3 tumor assessment and submitted to the BICR. Images will be submitted to an imaging core laboratory.